Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	419.67	115.85	118.37	234.2	118.72	147.7
Short-Term Investments	282.3	480.22	217.63	128.6	622.2	220.31
Cash & Short-Term Investments	701.96	596.07	336	362.79	740.92	368.01
Cash Growth	5.35%	77.40%	-7.38%	-51.03%	101.33%	-12.64%
Receivables	346.04	308.46	234.21	231.07	90.98	97.73
Inventory	185.8	141.86	127.6	100.12	53.91	60.75
Prepaid Expenses	94.96	38.95	48.61	45.02	40.48	28.27
Total Current Assets	1,329	1,085	746.42	739.01	926.29	554.76
Property, Plant & Equipment	71.42	75.04	74.94	75.57	8.79	10.59
Goodwill	416.82	416.82	416.82	409.05	-	-
Other Intangible Assets	348.54	401.83	472.88	546.65	-	-
Long-Term Deferred Tax Assets	-	3.86	4.39	44.43	155.43	-
Other Long-Term Assets	55.7	80.6	17.82	26.8	13.91	14.57
Total Assets	2,221	2,063	1,733	1,842	1,104	579.92
Accounts Payable	15.36	10.25	11.82	17.69	1.54	1.93
Accrued Expenses	111.18	121.8	100.68	97.66	22.17	19.08
Current Portion of Long-Term Debt	710.69	-	-	13.33	89.42	397.23
Current Portion of Leases	-	7.05	-	2.1	2.28	1.4
Current Unearned Revenue	-	-	-	-	1.75	1.75
Total Current Liabilities	837.23	139.1	112.49	130.79	117.15	421.39
Long-Term Debt	800.07	1,506	1,499	1,493	787.26	-
Long-Term Leases	28.1	23.65	32.2	32.69	0.54	3.47
Long-Term Unearned Revenue	-	-	-	-	2.53	4.03
Other Long-Term Liabilities	43.7	31.11	5.52	15.47	-	-
Total Liabilities	1,717	1,700	1,649	1,672	907.48	428.88
Common Stock	0.12	0.12	0.13	0.14	0.14	0.14
Additional Paid-In Capital	23.91	-	2.41	27.37	256.35	625.48
Retained Earnings	502.15	359.87	90.55	143.22	-58.91	-474.59
Comprehensive Income & Other	-22.26	3.83	-9.28	-0.92	-0.62	0.02
Shareholders' Equity	503.92	363.82	83.81	169.8	196.95	151.05
Total Liabilities & Equity	2,221	2,063	1,733	1,842	1,104	579.92
Total Debt	1,539	1,537	1,531	1,541	879.49	402.1
Net Cash (Debt)	-836.9	-940.43	-1,195	-1,178	-138.57	-34.08
Net Cash Per Share	-6.66	-7.27	-8.91	-8.38	-0.94	-0.24
Filing Date Shares Outstanding	117.6	123.15	126.82	135.37	137.7	135.21
Total Common Shares Outstanding	117.52	123.14	126.77	135.15	137.5	134.97
Working Capital	491.52	946.24	633.93	608.22	809.14	133.38
Book Value Per Share	4.29	2.95	0.66	1.26	1.43	1.12
Tangible Book Value	-261.45	-454.83	-805.89	-785.9	196.95	151.05
Tangible Book Value Per Share	-2.22	-3.69	-6.36	-5.81	1.43	1.12
Machinery	61.96	59.28	50.78	43.13	18.26	17.25
Leasehold Improvements	7.43	7.01	6.99	6.73	1.63	1.63
Order Backlog	-	99.9	-	-	-	-

Updated Nov 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q